Press Release

Registered & Corporate Office: AMANTA HEALTHCARE LIMITED 8th Floor, Shaligram Corporates, CJ Marg, Ambli, Ahmedabad–380058, Gujarat, INDIA. Tel.: 079 – 67777600 Email: info@amanta.co.in Website: www.amanta.co.in CIN: L24139GJ1994PLC023944 November 4, 2026 To, To, Sr. General Manager Sr. General Manager Listing Department National Stock Exchange of India Limited BSE Limited Exchange Plaza, C-1, Block G Phiroze Jeejeebhoy Towers, Bandra Kurla Complex Dalal Street, Mumbai – 400 001. Bandra (E), Mumbai – 400 051. Scrip Code: 544502 Trading Symbol: AMANTA Dear Sir/ Madam, Sub: Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations") - Press Release With reference to the captioned subject, please find enclosed herewith Press Release on the Financial Results for the quarter and half year ended September 30, 2026. You are requested to take the same on your records. Thanking you. Yours sincerely, For AMANTA HEALTHCARE LIMITED NIKHITA DINODIA COMPANY SECRETARY & COMPLIANCE OFFICER Encl.: As above Factory: 876, N.H. No. 8, Hariyala, Kheda – 387411, Gujarat, India. Tel 2694287700 Fax 2694287720 Amanta Healthcare Limited announces Q2 & H1FY27 Results Q2FY27 revenue grew 17% YoY, with PAT growth outpacing topline at 26%. SteriPort Line 3 commissioned, with SVP expansion poised to drive the next phase of growth. Ahmedabad, November 3rd, 2026: Amanta Healthcare Limited (BSE: 544502, NSE: AMANTA) today announced the unaudited financial results for the quarter ended September 30, 2026. Rs. in Cr. Q2FY27 Q2FY26 H1FY27 H1FY26 Revenue 83.13 70.89 151.94 136.19 EBITDA* 17.95 14.72 33.13 30.58 EBITDA Margin% 21.6% 20.8% 21.8% 22.4% PAT 4.86 1.21 8.17 4.71 PAT Margin% 5.85% 1.70% 5.38% 3.46% *EBITDA includes other income Q2FY27 Key Highlights: • Strong revenue growth: Q2FY27 revenue stood at ₹83.13 crore, up 17.3% YoY, achieved by combination of Price Increase and sale from New Line. H1FY27 revenue was ₹151.94 crore, up 11.6% YoY. • Operational performance strengthens: EBITDA for Q2FY27 stood at ₹17.95 crore (includes other income), up 21.9% YoY from ₹14.72 crore in Q2FY26. EBITDA margin expanded by ~80 bps to 21.6% from 20.8%, supported by a 4.5% YoY decline in other expenses even as revenue grew 17.3%. H1FY27 EBITDA is ₹33.13 crore, up 8.4% YoY. • Profitability up sharply: PAT for Q2FY27 stood at ₹4.86 crore versus ₹1.21 crore in Q2FY26 (which was after a ₹2.63 crore exceptional item), resulting in a PAT margin of 5.85%. PBT before exceptional items grew 39% YoY to ₹6.83 crore, while finance costs rose 13.4% to ₹5.84 crore. H1FY27 PAT was ₹8.17 crore, up 12% YoY. • Capacity expansion to drive the next leg of growth: SteriPort Line 3 was commissioned in the first week of September 2026 at the existing Kheda facility, raising SteriPort capacity by 75% from 6.6 crore to 11.6 crore bottles, and is expected to contribute ~₹60 crore of revenue in FY27 (₹110–120 crore a year at optimal utilisation). The SVP expansion, taking capacity from 20.9 crore to 31.7 crore units, is targeted for Q1FY28. The 10.8 MW captive solar plant, generating since the end of Q1FY27, is expected to save ~₹9 crore annually. Commenting on the performance for the quarter, Bhavesh Patel, Chairman & Managing Director, Amanta Healthcare Limited said, “Q2FY27 was a strong quarter for Amanta Healthcare, with revenue growing 17.3% YoY to ₹83.13 crore. EBITDA rose 21.9% YoY to ₹17.95 crore, including other income, with margins expanding to 21.6%. PAT stood at ₹4.86 crore, a margin of 5.85%, compared to ₹1.21 crore in Q2FY26. For H1FY27, revenue stood at ₹151.94 crore and PAT at ₹8.17 crore. The capacity-led growth phase has now begun. SteriPort Line 3 was commissioned in the first week of September, lifting SteriPort capacity by 75%, and the SVP expansion targeted for Q1FY28 will add inhalation, ophthalmic and diluent capacity in our highest-margin segment. Our 10.8 MW captive solar plant, operational since the end of Q1FY27, is expected to save around ₹9 crore annually. With these initiatives progressing well, we are confident of building greater scale, enhancing profitability and unlocking sustainable growth opportunities across both domestic and export markets.” ABOUT AMANTA HEALTHCARE LIMITED Amanta, a pharmaceutical company engaged in development, manufacturing, and marketing of sterile liquid products, including both large and small volume parenteral (LVPs and SVPs). Using advanced Aseptic Blow-Fill-Seal (ABFS) and Injection Stretch Blow Moulding (ISBM) technologies, the Company serves six therapeutic segments with products such as IV fluids, diluents, ophthalmic and respiratory care, and irrigation solutions. The packaging includes a wide range of closure systems and container volumes from 2 ml to 1000 ml. Amanta is led by experienced Management including our Promoter & CMD – Mr. Bhavesh Patel, a Mechanical Engineer and master’s degree in management with more than 30 years of experience. For more information, please visit: www.amanta.co.in Company contact Investor Relations Team Email: cs@amanta.co.in, Soumya Chhajed Tel: 079 6777 7600 Email- soumya@goindiaadvisors.com Mobile: +91-8619707750 Amanta Healthcare Ltd. 8th Floor, Shaligram Corporates, C. J. Marg, Ambli, Ahmedabad 380058 Gujarat, India.